Management of Uncontrolled Diabetes in Patients with Cognitive Impairment

Simplification of Insulin Regimens

The American Diabetes Association recommends simplifying to once-daily long-acting basal insulin, such as insulin glargine, combined with caregiver support, for patients with cognitive impairment who cannot remember to dose insulin 1
Reducing injection frequency to once-daily basal insulin is a critical intervention, rather than multiple daily injections, to reduce the risk of hypoglycemia and improve adherence 1
Switching to once-daily long-acting basal insulin, such as glargine U-100, U-300, detemir, degludec, or NPH, administered at the same time each day, preferably when a caregiver can supervise, can improve glycemic control and reduce hypoglycemia risk 1
Discontinuing complex multiple daily injection regimens that require the patient to remember prandial insulin doses throughout the day can reduce the risk of hypoglycemia and improve adherence 1

For patients with mild-to-moderate cognitive impairment, the American Diabetes Association recommends targeting an A1C <8.0% (64 mmol/mol) to balance glycemic control against hypoglycemia risk 1
For patients with moderate-to-severe cognitive impairment, the focus should be on avoiding hypoglycemia and symptomatic hyperglycemia, rather than targeting a specific A1C level 1

For patients with type 2 diabetes and residual beta-cell function, consider transitioning to non-insulin agents with low hypoglycemia risk, such as GLP-1 receptor agonists, SGLT-2 inhibitors, DPP-4 inhibitors, or metformin, if appropriate for their diabetes type and severity 1
GLP-1 receptor agonists, such as weekly formulations, can provide glucose-lowering without hypoglycemia risk 1
SGLT-2 inhibitors offer once-daily dosing with cardiovascular and renal benefits, and minimal hypoglycemia risk 1
DPP-4 inhibitors are well-tolerated with once-daily dosing and low hypoglycemia risk 1
Metformin remains an appropriate option if renal function permits (eGFR considerations apply) 1

Connected insulin pens can track dose timing and amounts, allowing caregivers and clinicians to monitor adherence remotely 2
Insulin pens with memory functions can help patients and caregivers verify whether doses were taken 2
Continuous glucose monitoring (CGM) allows remote monitoring by caregivers to detect hypo- and hyperglycemia without requiring patient action 2
Insulin injection aids may help patients with dexterity or vision issues dose more accurately when cognitive function is preserved enough for supervised self-administration 2

Identifying and training a reliable caregiver to supervise or administer insulin is crucial for patients with cognitive impairment 3
Caregivers should be instructed on insulin administration technique, dose verification, and hypoglycemia recognition 3
Prescribing glucagon and training caregivers on its use for severe hypoglycemia episodes is essential 3

Severe or recurrent hypoglycemia is an absolute indication for treatment simplification, regardless of A1C level 4
Wide glucose excursions suggest the current regimen is too complex for the patient to manage safely 1
Significant changes in social circumstances, such as loss of caregiver, change in living situation, or financial difficulties, necessitate immediate regimen simplification 1
Cognitive or functional decline following acute illness requires reassessment and likely simplification of the diabetes treatment plan 1

The American Diabetes Association recommends a target A1C of <8.0% (64 mmol/mol) for elderly patients with mild-to-moderate cognitive impairment, while those with moderate-to-severe cognitive impairment should focus on avoiding hypoglycemia and symptomatic hyperglycemia 5, 6, 7
For patients with mild-to-moderate cognitive impairment, a less stringent A1C target reflects the impact of comorbidities on self-management abilities and the increased risk of hypoglycemia 5, 8
Tight glycemic control offers no mortality benefit in this population and substantially increases the risk of hypoglycemia 5, 9

For patients with mild-to-moderate cognitive impairment, the primary goal is to maintain an A1C <8.0% (64 mmol/mol) 5, 10, 8, 6, 11, 12, 7
For patients with moderate-to-severe cognitive impairment, the primary goal is to avoid hypoglycemia and symptomatic hyperglycemia, rather than relying on A1C targets 8, 12, 7
The most important outcomes for patients with moderate-to-severe cognitive impairment are the maintenance of cognitive and functional status, rather than glycemic metrics 5, 9

Intensive glucose control targeting A1C <6.0% significantly increases the risk of hypoglycemia requiring assistance in older adults 6
The ACCORD MIND trial found that intensive glucose control did not benefit brain structure or cognitive function 13
Hypoglycemia should be diligently avoided as it increases the risk of cognitive decline 13
Preventing hypoglycemia reduces the risk of falls, fractures, and functional impairment 5, 9

For community-dwelling patients in rehabilitation, the glucose target is 100-200 mg/dL (5.6-11.1 mmol/L) 12, 7
For patients in long-term care or with end-stage illness, the focus should be exclusively on avoiding hypoglycemia and symptomatic hyperglycemia 8, 12, 7
Comfort and quality of life take precedence over glycemic metrics in this population 5, 7

Deintensification triggers include severe or recurrent hypoglycemia, cognitive dysfunction, depression, anorexia, or inconsistent eating patterns 5, 7, 9
Simplification triggers include the inability to manage complex insulin regimens, patient desire for fewer injections and fingerstick monitoring, or significant changes in social circumstances 5, 8, 12

Pursuing A1C <7% in patients with moderate-to-severe cognitive impairment is not recommended due to the increased risk of hypoglycemia 5, 6
Ignoring A1C entirely in mild-to-moderate impairment can lead to poor control and accelerated cognitive decline 5, 8
Relying on A1C in conditions affecting red blood cell turnover, such as hemodialysis or recent transfusion, is not recommended; instead, use plasma glucose and fingerstick readings 13, 12
Avoiding medications with high hypoglycemia risk, such as sulfonylureas and meglitinides, is recommended in the context of cognitive dysfunction and inconsistent eating 5, 7